Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. All News
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
Delayed Japan Exchange  -  01:00:00 2023-01-27 am EST
8149.00 JPY   -1.59%
01/27Disappointing Tech Earnings, Outlook Weigh on Exchange-Traded Funds, Equity Futures Pre-Bell
MT
01/27Biogen, Eisai Say European Medicines Agency Accepts for Review Regulatory Application for Alzheimer's Disease Drug
MT
01/26Eisai : Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about EISAI CO., LTD.
01/27Disappointing Tech Earnings, Outlook Weigh on Exchange-Traded Funds, Equity Futures Pre..
MT
01/27Biogen, Eisai Say European Medicines Agency Accepts for Review Regulatory Application f..
MT
01/26Eisai : Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer..
AQ
01/26BioArctic, Eisai's Regulatory Application for Alzheimer's Disease Drug Accepted in EU
MT
01/26Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization
DJ
01/26European Medicines Agency accepts Marketing Authorization Application for lecanemab as ..
AQ
01/26Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early ..
CI
01/26Eisai Co., Ltd. and Biogen Inc. Announce European Medicines Agency Accepts Marketing Au..
CI
01/25Lonza underscores growth prospects with share buy-back, dividend hike
RE
01/23Sinking Yen, Wall Street Cues Drive Tokyo Shares Higher
MT
01/20Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts
RE
01/19Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug
RE
01/17Eisai : Aims to advance gastrointestinal cancer treatment with research across multiple tu..
PU
01/17Eisai, Biogen Seek Approval for Alzheimer's Drug in Japan
MT
01/16Yen Boost, Prospect of Monetary Policy Shift Spook Japanese Traders; Daiichi Sankyo Fil..
MT
01/16Japan's Nikkei ends at more than a week low as BOJ capitulation bets push up yen
RE
01/15Japan's Nikkei dives 1% as BOJ capitulation bets push up yen
RE
01/15Eisai files for approval of Alzheimer's drug in Japan
RE
01/15BioArctic, Eisai Submit Regulatory Application for Alzheimer's Disease Drug in Japan
MT
01/15Eisai, Biogen apply for Alzheimer's drug approval in Japan
AQ
01/15Eisai files for approval of Alzheimer's drug in Japan
RE
01/15Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofi..
CI
01/12Eisai : Launches renewed sustainability page
PU
01/12Modalis Therapeutics Corporation Announces Notice of Termination of A Research Collabor..
CI
01/10BioArctic, Eisai Seek EU Nod For Early Alzheimer's Disease Drug
MT
01/10BioArctic's partner Eisai submits marketing authorization application for lecanemab as ..
AQ
01/10Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early ..
CI
01/10Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanem..
CI
01/10Japan's Nikkei closes at 2-week high on tech boost
RE
01/09Japan's Nikkei gains as tech shares track U.S. peers higher
RE
01/09Global markets live: Alibaba, Qiagen, Macy's, Oracle, Chevron...
MS
01/09Trending: Biogen, Eisai Win FDA Nod for Alzheimer's Drug
DJ
01/09Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approva..
AQ
01/09Eisai, Biogen's Alzheimer's drug price should not dent demand - analysts
RE
01/09FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Tr..
AQ
01/09MarketScreener's World Press Review: January 9
MS
01/08Eisai, Biogen Get US Drug Regulator's Nod for Alzheimer's Drug
MT
01/08BioArctic, Eisai Secure US FDA Approval For Alzheimer's Disease Drug
MT
01/08Reuters-schedule/…
RE
01/07Explainer : New drug slows Alzheimer's but comes with caveats
AQ
01/07Reuters-schedule/…
RE
01/07Transcript : Eisai Co., Ltd. - Special Call
CI
01/06Eisai : Submits Supplemental Biologics License Application to FDA for Traditional Approval..
PU
01/06Eisai files for full FDA approval for Alzheimer's drug Leqembi
RE
01/06BioArctic's partner Eisai submits supplemental Biologics License Application to FDA for..
AQ
01/06U.S. regulators OK Alzheimer's drug developed by Japan's Eisai
AQ
01/06Factbox-Who can get the newly approved Eisai and Biogen Alzheimer's drug?
RE
01/06US approves Alzheimer's drug that modestly slows disease
AQ
01/06ADRs End Higher, Shell and Eisai Trade Actively
DJ
01/06Wall St rallies as jobs, services data calm rate hike worries
RE
01/06Alzheimer's drug that modestly slows disease OK'd by FDA
AQ
01/06Eisai : FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathwa..
PU
01/06Eisai says new Alzheimer's drug to cost $26,500 annually
RE
01/06Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under th..
CI
01/06Eisai Co., Ltd. Announces LEQEMBI (Lecanemab-Rimb) Has the Potential to Make Difference..
CI
01/06U.S. FDA approves Eisai, Biogen's Alzheimer's drug
RE
01/06U.S. FDA approves Eisai, Biogen's Alzheimer's drug
RE
01/05Biogen splits R&D division ahead of key decision on Alzheimer's drug
RE
01/04Japan's Nikkei tracks Wall St weakness to end at near 10-month low
RE
01/03Japan's Nikkei hits over 3-month low tracking subdued Wall Street
RE
2022Yasuda Logistics Corporation (TSE:9324) agreed to acqu..
CI
2022Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report
RE
2022Biogen's Partner Eisai Begins Biologics License Application for Lecanemab in China
MT
2022BioArctic's partner Eisai publishes statement relating to article on lecanemab in Scien..
AQ
2022Japan drugmaker Eisai's shares slump after report of 3rd death in Alzheimer's trial
RE
2022Japan's Nikkei slips as chip stocks weigh, set for worst week since June
RE
2022Eisai Initiates BLA Submission of Data for Lecanemab in China
CI
2022BioArctic's partner Eisai initiates BLA submission of data for lecanemab in China
AQ
2022Sysmex says Japan approves blood test for Alzheimer's marker
RE
2022Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United Stat..
AQ
2022Eisai : TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA« (perampanel) CIII IN UNITED STAT..
PU
2022Catalyst Pharmaceuticals Agrees to Acquire US Rights for Epilepsy Medication From Eisai..
MT
2022Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA(R) CIII from Eisa..
CI
2022Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensiv..
AQ
2022Retail Sector Strength Edges Japan Shares Into Green
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on EISAI CO., LTD.